NEW YORK (GenomeWeb) – Becton Dickinson said today that its fiscal second quarter revenues slipped almost 1 percent year over year. 

For the three months ended March 31, the Franklin Lakes, New Jersey-based company posted revenues of $2.05 billion compared to $2.07 billion in the year-ago quarter. It matched the analysts' average estimate. 

On a currency-neutral basis, revenues in Q2 2015 were up 5 percent year over year, the company said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.